InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$191.75

2026-10-16

Market Cap

$52.2B

Volume

1.4M

52-Wk High

$195.99

52-Wk Low

$127.59

Trailing PE

57.8

P/S

2.51

Gross Margin

46.1%

Net Margin

4.5%

ROE

4%

ROIC

4%

Piotroski

7/9

Altman Z

2.2

1-Yr Return

+4.0%

5-Yr Return

-12.9%

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

SectorHealthcareIndustryMedical - Instruments & SuppliesExchangeNYSEMarket Cap$52.2BEmployees72,000 (SEC-filed)CEOThomas E. Polen Jr.IPO1973-02-21CountryUS

1 Becton Drive, Franklin Lakes, NJ 07417-1880 · Tel 201 847 6800 · bd.com

INSIDERSTREET SCORE43 / 100Street mean $188.33 (6 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$2M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · BDX +4.0% · S&P 500 +15.9% · spread -11.9pp

7 Years vs S&P 500 · BDX -12.9% · S&P 500 +189.9% · spread -202.8pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE43of 100

Score Breakdown

Profitability	33/100
Growth	18/100
Momentum	53/100
Quality	68/100
Earnings Quality	80/100
Balance Sheet	42/100
Value	43/100
Risk (safety)	50/100
Overall	42.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
RMD	82
MDLN	43
WST	72
ISRG	80
HOLX	56
SOLV	37
BDX	43

IS Score Trend — quarterly

15 quarters, 23 Q1 to 26 Q3. Peak 58 in 25 Q1, latest 43 — -16 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY43 / 100IS Score 42.6 / 100 · -15.6 from peak of 58

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 80 / 100 · Power +60 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 43, price structure 80 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 42.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 51 → 51 → 44 → 43	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Site Convergence Score1 of 4top 66% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-09-11

Insider Buys (180d)0none disclosed

ETF Funds (30d)382 up / 403 downnet -21 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Feld Michael	EVP, Chief Revenue Officer	2026-09-28	SELL	76	$0.01M	19,644
Roque Vitor	EVP & Chief Financial Officer	2026-09-02	TAX W/H	190	—	8,041
Feld Michael	EVP, Chief Revenue Officer	2026-08-26	SELL	165	$0.03M	19,720
Feld Michael	EVP, Chief Revenue Officer	2026-08-20	TAX W/H	1,049	—	19,885
Polen Thomas E Jr	director, Chairman, CEO and President	2026-08-13	EXERCISE	43,278	$7.24M	153,441
Polen Thomas E Jr	director, Chairman, CEO and President	2026-08-13	D-Return	39,126	$7.24M	114,315
Polen Thomas E Jr	director, Chairman, CEO and President	2026-08-13	SELL	4,152	$0.77M	110,163
Polen Thomas E Jr	director, Chairman, CEO and President	2026-08-13	EXERCISE	43,278	$7.24M	0

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	13	12,244	$2.1M	Counted
M — Exercises (paired A/D)	2	63,487	$9.8M	None — mechanics
F — Tax withholding	4	4,320	—	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$2.1M13 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Filer	Shares registered	Est. proceeds
2026-09-28	Michael Feld	76	$0.0M
2026-08-26	Michael Feld	165	$0.0M
2026-08-20	Richard Byrd	1,330	$0.2M
2026-08-13	Thomas Polen	4,152	$0.8M
Trailing 12 mo	27 filings	44,332	$8M

Filed	Form	Reporting person	% of class	Shares
2026-08-07	SCHEDULE 13G	STATE STREET CORPORATION	5.40%	15.0M sh
2026-04-29	SCHEDULE 13G	Vanguard Portfolio Management	5.40%	15.4M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.51%	21.4M sh
2026-01-30	SCHEDULE 13G/A	The Vanguard Group	12.85%	36.7M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Thomas H. Kean	House	SELL	$1,001 - $15,000	2026-05-21	2026-06-19
Thomas Kean	House	SELL	$1,001 - $15,000	2026-05-21	2026-06-19
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2024-02-15	2024-03-15
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2024-02-15	2024-03-14
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2024-02-15	2024-03-14

House 12-Mo8 trades2 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)0

13F Shares0M0.0% of shares out

New / Closed0 / 0positions, QoQ

Increased / Reduced0 / 0positions, QoQ

Put/Call (13F)—option positions

Free Float99.8%272M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fort Washington Investment Advisor	1.1M	$199M
Davenport & Co Llc	607,325	$109M
Avity Investment Management Inc.	209,385	$37M
Auto-Owners Insurance Co	182,355	$33M
Cacti Asset Management Llc	180,296	$33M
Cardinal Capital Management, Inc.	177,450	$32M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.5B
VSMPX	0.1%	$1.5B
VTSAX	0.1%	$1.5B
VTI	0.1%	$1.5B
VFIAX	0.1%	$1.3B
VFFSX	0.1%	$1.3B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session30.7%2026-10-15

20-Day Avg40.5%50-day 51.1%

TrendFalling20d vs 50d

By Market CenterQ: 29% · N: 52% · B: 54%latest session

Weekly Notional ($B)

Where BDX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	3.1M	39 sh
Ubsa Ubs Ats	2.6M	51 sh
Ebxl Level Ats	1.8M	29 sh
Sgmt Sigma X2	1.8M	40 sh
Mlix Instinct X	1.2M	63 sh
Mspl Ms Pool (Ats-4)	1.0M	145 sh

Where a dollar of Becton, Dickinson and Company revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$12.8B	59%
Europe	$4.7B	22%
Asia	$3.1B	14%
Others Country	$1.2B	6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

BDX (live moat model)Peer median: RMD · MDLN · WST · ISRG · HOLX

Component scores from the live moat model. Peer median illustrative.

Moat score 51/100 — Weak; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Thomas E. Polen Jr.	President, Chief Executive Officer & Chairman
Michael C. Feld	Executive VP & Chief Revenue Officer
Vitor Roque	Executive Vice President & Chief Financial Officer
Manish Sinha	Executive Vice President & Chief People Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+8.4%

Next Report2026-11-05

Income Quality3.29OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+19.0%	-1.4%	+2.7%	+4.2%	+8.2%
Gross profit	+27.0%	-1.8%	-3.6%	+11.7%	+8.8%
Operating income	+146.7%	+1.4%	-7.5%	+13.5%	+7.6%
Net income	+139.4%	-15.0%	-16.6%	+14.9%	-1.6%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	19.1	18.9	19.4	20.2	21.8
Cost of revenue	10.5	10.4	11.2	11.1	11.9
Gross profit	8.6	8.5	8.2	9.1	9.9
R&D expense	1.3	1.3	1.2	1.2	1.3
SG&A expense	4.7	4.7	4.7	4.9	5.3
Operating income	2.2	2.3	2.1	2.4	2.6
EBITDA	4.4	4.4	4.4	4.8	5.0
D&A	2.2	2.2	2.3	2.3	2.5
Pretax income	1.7	1.8	1.7	2.0	1.9
Income tax	0.1	0.1	0.1	0.3	0.2
Net income	2.1	1.8	1.5	1.7	1.7
Diluted EPS ($)	6.85	5.88	4.94	5.86	5.83
Diluted shares (M)	292	287	288	291	287

Operating CF$3B

CapEx$1B

Free cash flow$3B

SBC$0B

Buybacks$1B

Net cash change$-1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.0	1.4	1.7	0.9
ST investments	0.0	0.0	0.4	0.0
Receivables (net)	2.2	2.5	3.0	3.0
Total current assets	8.1	8.7	10.5	9.3
PP&E (net)	6.0	6.6	6.8	7.0
Goodwill + intangibles	36.9	35.5	37.4	36.0
Total assets	52.9	52.8	57.3	55.3
Accounts payable	1.7	1.6	1.9	2.0
Short-term debt	2.2	1.1	2.2	1.6
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	7.8	6.6	9.0	8.3
Long-term debt	13.9	14.7	17.9	17.6
Total liabilities	27.7	27.0	31.4	29.9
Shareholders' equity	25.3	25.8	25.9	25.4

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.8	1.5	1.7	1.7
D&A	2.2	2.3	2.3	2.5
Stock-based compensation	0.2	0.3	0.2	0.3
Working capital change	(1.4)	(0.8)	0.3	(0.8)
Operating cash flow	2.6	3.0	3.8	3.4
Capital expenditures	(1.0)	(0.9)	(0.7)	(0.8)
Investing cash flow	(3.2)	(0.7)	(5.5)	(0.8)
Buybacks	(0.5)	0.0	(0.5)	(1.0)
Dividends paid	(1.1)	(1.1)	(1.1)	(1.2)
Debt issuance / (repay)	(0.1)	(0.7)	3.8	(1.3)
Financing cash flow	(0.6)	(2.0)	2.1	(3.6)
Free cash flow	1.7	2.1	3.1	2.7

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	8.8%	7.3%	5.8%	6.7%	6.5%	4%
ROA	3.9%	3.3%	2.8%	3.1%	3.0%	1.9%
ROIC	6.4%	5.2%	4.8%	5.0%	5.3%	3.7%
Gross margin	45.1%	44.9%	42.2%	45.2%	45.4%	46.1%
Operating margin	11.8%	12.1%	10.9%	11.9%	11.8%	9.8%
Net margin	10.9%	9.4%	7.7%	8.4%	7.7%	4.5%
EBITDA margin	23.0%	23.4%	22.7%	23.9%	22.7%	21.4%
FCF margin	17.1%	8.8%	10.9%	15.2%	12.2%	—
VALUATION
P/E	30.81	33.91	48.88	39.54	31.85	57.8
P/B	2.72	2.39	2.81	2.64	2.11	2.2
P/S	3.23	3.20	3.74	3.38	2.45	2.51
P/FCF	18.87	36.34	34.30	22.21	20.02	20.0
EV/EBITDA	16.57	17.09	19.76	18.32	14.48	15.3
EV/Revenue	4.00	3.99	4.49	4.27	3.29	3.3
Earnings yield	3.2%	2.9%	2.0%	2.5%	3.1%	1.79%
FCF yield	5.3%	2.8%	2.9%	4.5%	5.0%	4.99%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.33	1.04	1.31	1.17	1.11	0.87
Quick ratio	0.92	0.63	0.81	0.74	0.64	0.51
Debt / equity	0.74	0.64	0.62	0.78	0.76	0.69
Debt / assets	32.7%	30.3%	30.1%	35.1%	34.7%	33.1%
Net debt / EBITDA	3.18	3.41	3.28	3.81	3.70	3.61
Interest coverage	5.50	5.48	4.68	4.85	4.07	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.37	0.35	0.37	0.37	0.39	0.41
Receivables turnover	8.41	8.31	8.20	7.25	7.25	8.8
DSO (days)	43	44	45	50	50	41
DPO (days)	53	60	54	59	59	—
Cash conversion cycle	84	88	96	110	110	149
GROWTH (YoY)
Revenue growth	16.6%	-5.5%	2.7%	4.2%	8.2%	—
Net income growth	139.1%	-15.0%	-16.6%	16.3%	-2.8%	—
EPS growth	143.0%	-14.4%	-18.3%	17.1%	-1.6%	—
FCF growth	25.2%	-51.4%	27.4%	45.3%	-13.1%	—
PER SHARE ($)
EPS (diluted, TTM)	7.25	6.21	5.07	5.94	5.84	3.42
Book value / share	82.04	88.22	88.13	89.09	88.43	88.86
Revenue / share	69.18	65.85	66.18	69.44	76.06	75.84
FCF / share	11.84	5.79	7.23	10.57	9.30	9.48
Cash / share	7.95	3.54	4.87	7.44	2.99	2.58
SHAREHOLDER RETURN & SCORES
Buyback yield	2.7%	0.8%	0.0%	0.0%	1.9%	6.00%
Altman Z-Score	2.22	2.21	2.57	2.23	2.06	2.2
Piotroski F-Score	7	5	6	6	7	7/9
Beneish M-Score	-2.70	-2.60	-2.31	-2.61	-2.66	-2.91

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	2.2	Grey zone	Grey
Income quality	3.29	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.91	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.59
Interest burden	0.75
Operating margin	10.2%
Asset turnover	0.39×
Financial leverage	2.12×
= ROE	4%

Growth Quality (live)	Value
Revenue stability	0.53
Earnings stability	0.78
Earnings persistence	0.83
Revenue CAGR 3y	3.0%
EPS CAGR 3y	-16.0%
FCF CAGR 3y	14.4%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield6.00%

Dividend Yield2.07%

Total Shareholder Return10.23%cash yield

SBC / Revenue1.2%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
RMD	$33.6B	22.9	24%	26.2%	+9.9%	7/9	-11.3%
MDLN	$31.5B	41.8	3%	0.8%	—	4/9	-12.3%
WST	$27.0B	48.8	19%	17.7%	+12.4%	9/9	+43.8%
ISRG	$150.7B	48.2	17%	28.3%	+20.7%	7/9	-1.8%
HOLX	$17.0B	30.3	11%	17.1%	+2.2%	6/9	—
SOLV	$14.6B	10.4	34%	4.2%	-0.9%	7/9	—
BAX	$13.1B	-12.4	-16%	4.3%	+5.4%	3/9	—
RGEN	$11.1B	237.1	2%	2.5%	+16.5%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

34 Analysts

Str Sell (0)Sell (1)Hold (17)Buy (16)Str Buy (0)

Mean Target (qtr)$188.336 targets

Target vs. Price-1.8%last-quarter mean

Next Report2026-11-05street $4.07

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$19.30B	$19.98B / $19.12B	$12.67	$12.76 / $12.08	8
FY2027	$19.70B	$20.38B / $19.44B	$13.24	$13.80 / $13.05	8
FY2028	$20.47B	$21.16B / $20.18B	$14.16	$16.47 / $11.84	2

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$165.00	-14.0%	1
Last Quarter	$188.33	-1.8%	6
Last Year	$178.85	-6.7%	18
All Time	$200.49	+4.6%	39

Rolling mean of published targets vs. last close $191.75. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

5/5

ROE

2/5

ROA

4/5

Debt/Eq

1/5

P/E

1/5

P/B

4/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

BDX +4.0% vs S&P 500 +15.9% — spread -11.9pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$183.35	+8.40	+4.58%	Above
SMA 50	$183.68	+8.07	+4.39%	Above
SMA 200	$164.14	+27.61	+16.82%	Above
EMA 9	$187.57	+4.18	+2.23%	Above
EMA 21	$184.69	+7.06	+3.82%	Above
EMA 50	$180.26	+11.49	+6.37%	Above
EMA 200	$171.91	+19.84	+11.54%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6020 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%82

Volume 20%69

Volatility 10%100

Patterns 15%38

This Week100% bullishof 11 price-based votes

4 Weeks Ago36%+64 pts since

12 Weeks Ago27%+73 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$183.35

Price vs SMA 50$183.68

Price vs SMA 200$164.14

EMA 9/21 Cross187.6/184.7

SMA 50/200Golden

ADX DirectionADX 26

Supertrend$180

Parabolic SAR$180

SMA Slope0.530

RSI63.4

Stochastic K/D89/90

StochRSI K/D92/92

Williams %R-21

CCI191

TSI vs Signal16.6

CMO26.7

ROC8.34%

OBV SignalAccum

Chaikin MF0.170

MFI58

Force Index2M

Elder Ray Bull11.08

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 90

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$192.54 / $195.56 / $197.37	S1 / S2	$190.73 / $187.71
Bollinger (20,2)	$174.44 – $192.26	Squeeze	Off
52-wk range	$140.11 – $202.75	Off 52-wk high	-5.5%
ATR (14)	$4.25 (2.2%)	Historical vol	22.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+3.1%Jan60%

-1.5%Feb50%

+0.3%Mar52%

+0.5%Apr55%

-0.7%May40%

+1.4%Jun65%

+2.4%Jul75%

+0.2%Aug60%

-0.9%Sep45%

-0.1%Oct55%

+2.3%Nov75%

+2.0%Dec80%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	BDX	S&P 500
Weekly volatility (σ, 1y)	4.43%	1.83%
Best / worst week (1y)	+10.6% / -17.3%	—
Max drawdown (5y, monthly)	-44.9%	—
1-week VaR (95%)	-5.4%	—
Beta (5y)	0.28	1.00

BDX EQUITY WEATHER (LIVE)CLOUDY · +8

Trend+43

Momentum+59

Volume-41

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 157 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+7.6+17.9 vs industry

Trend+43.3+42.6 vs industry

Momentum+59.3+60.5 vs industry

Volume-41.2-58.3 vs industry

Reading	BDX	Medical - Instruments & Supplies n=284	Healthcare n=5,272	All US symbols n=70,435
Overall	+7.6	-10.3	-24.0	-20.5
Trend	+43.3	+0.7	-25.6	-21.3
Momentum	+59.3	-1.1	-28.5	-15.8
Volume	-41.2	+17.1	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Thomas E. Polen Chairman, Chief Executive Of	$17.1M	69% equity+incentive
Christopher J. DelOrefice Executive Vice Pre	$5.9M	66% equity+incentive
Michael C. Feld Executive Vice President, Ch	$4.1M	53% equity+incentive
Michael D. Garrison Executive Vice President	$3.6M	60% equity+incentive
Richard E. Byrd Executive Vice President and	$3.4M	59% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	76
Social	63
Governance	63
Composite ESG	67

Composite ESG Trend

Filed	8-K contents	Items
2026-08-06	Earnings Release; Exhibits	2.02,9.01
2026-07-22	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-29	Regulation FD	7.01
2026-05-20	Material Agreement; Financial Obligation; Exhibits	1.01,2.03,9.01
2026-05-12	Other Events; Exhibits	8.01,9.01
2026-05-07	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-07	Earnings Release; Exhibits	2.02,9.01
2026-04-29	Bylaws Amendment; Exhibits	5.03,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-08-06
Analyst estimates	dim/forward_estimates	3 rows · 2026-09-30 to 2028-09-30
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	not present for this symbol
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-07-27 to 2026-09-28
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-01-30 to 2026-08-07
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Becton, Dickinson and Company (BDX)

Monthly Net Insider Flow (000 shares)

Signal Summary

Becton, Dickinson and Company (BDX)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

Becton, Dickinson and Company (BDX)

Where BDX Trades in the Dark

Becton, Dickinson and Company (BDX)

3.8 · Employees (SEC filings)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Balance Sheet — Full

Cash Flow Statement — Full

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Street Price Target — Trajectory

Third-Party Composite Rating

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Family Scores (site weights)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)